1. Home
  2. LZB vs ZYME Comparison

LZB vs ZYME Comparison

Compare LZB & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo La-Z-Boy Incorporated

LZB

La-Z-Boy Incorporated

HOLD

Current Price

$39.63

Market Cap

1.5B

ML Signal

HOLD

Logo Zymeworks Inc.

ZYME

Zymeworks Inc.

HOLD

Current Price

$26.06

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LZB
ZYME
Founded
1927
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Home Furnishings
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.7B
IPO Year
1994
2022

Fundamental Metrics

Financial Performance
Metric
LZB
ZYME
Price
$39.63
$26.06
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
11
Target Price
$39.00
$38.90
AVG Volume (30 Days)
743.9K
625.2K
Earning Date
06-16-2026
05-07-2026
Dividend Yield
2.75%
N/A
EPS Growth
5.11
33.33
EPS
2.47
N/A
Revenue
$2,349,433,000.00
$105,965,000.00
Revenue This Year
$1.89
$183.10
Revenue Next Year
$2.09
N/A
P/E Ratio
$16.24
N/A
Revenue Growth
N/A
38.87
52 Week Low
$29.03
$11.86
52 Week High
$44.90
$29.75

Technical Indicators

Market Signals
Indicator
LZB
ZYME
Relative Strength Index (RSI) 55.66 59.90
Support Level $36.31 $22.44
Resistance Level $39.76 $26.75
Average True Range (ATR) 1.73 1.10
MACD -0.01 0.35
Stochastic Oscillator 46.29 71.80

Price Performance

Historical Comparison
LZB
ZYME

About LZB La-Z-Boy Incorporated

La-Z-Boy Inc is a U.S.-based company that manufactures, distributes, and retails upholstery furniture products. It is a producer of reclining chairs and distributors of residential furniture in the U.S. The company chiefly operates in the United States but also has secondary operations in Canada and other countries. The company's reportable segments include the Wholesale segment, which manufactures and imports upholstered furniture; Retail, which sells upholstered and case goods furniture to the end consumer and corporate and others. The majority of the company's revenue is derived from its Wholesale segment.

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Share on Social Networks: